Imlygic Disease Interactions
There are 4 disease interactions with Imlygic (talimogene laherparepvec).
Talimogene laherparepvec (applies to Imlygic) immunocompromised
Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
Talimogene laherparepvec is a live, attenuated herpes simplex virus. The use talimogene laherparepvec is contraindicated in patients who are immunocompromised as its administration in these patients may cause life-threatening disseminated herpetic infection.
References (1)
- (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Talimogene laherparepvec (applies to Imlygic) immunodeficiency
Major Potential Hazard, Moderate plausibility. Applicable conditions: Lymphoma, Leukemia
Do not administer talimogene laherparepvec to patients with a history of primary or acquired immunodeficient states, leukemia, lymphoma, AIDS or other clinical manifestations of infection with human immunodeficiency viruses, and those on immunosuppressive therapy.
References (1)
- (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Talimogene laherparepvec (applies to Imlygic) autoimmune disorders
Moderate Potential Hazard, Moderate plausibility.
The use of talimogene laherparepvec may result in immune-mediated events. Exercise care when using this agent in patients with underlying autoimmune disease or before continuing treatment in those patients that have developed immune-mediated events. Close monitoring is recommended.
References (1)
- (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Talimogene laherparepvec (applies to Imlygic) multiple myeloma
Moderate Potential Hazard, Moderate plausibility.
Plasmacytoma, in proximity to the injection site, has been reported after administration of talimogene laherparepvec in a patient with smoldering multiple myeloma. It is recommended to consider the risks and benefits of treatment in patients with multiple myeloma or in whom plasmacytoma develops during treatment. Close monitoring is recommended.
References (1)
- (2015) "Product Information. Imlygic (talimogene laherparepvec)." Amgen USA
Switch to consumer interaction data
Imlygic drug interactions
There are 300 drug interactions with Imlygic (talimogene laherparepvec).
Report options
More about Imlygic (talimogene laherparepvec)
- Imlygic consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Mekinist
Mekinist is used to treat melanoma, non-small cell lung cancer, thyroid cancer, solid tumors, and ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Interferon alfa-2b
Interferon alfa-2b systemic is used for angioblastoma, condylomata acuminata, conjunctival ...
Dacarbazine
Dacarbazine systemic is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Ipilimumab
ipilimumab (Yervoy) is an immunotherapy used for melanoma, renal cell carcinoma, non-small cell ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.